生物活性

• 描述Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02656849	Solid Tumor	Phase 2	Withdrawn(Development of BAY10... more >>00394 has been terminated by Bayer.) Collapse <<	May 2023	United States, Massachusetts ... more >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse <<
  NCT01573338	Small Cell Lung Carcinoma	Phase 1 Phase 2	Terminated	-	United States, Missouri ... more >> Saint Louis, Missouri, United States, 63110 United States, New York Buffalo, New York, United States, 14263-0001 United States, Ohio Cleveland, Ohio, United States, 44195 France Caen Cedex, France, 14033 Lyon Cedex, France, 69008 Marseille, France, 13005 Villejuif Cedex, France, 94805 Korea, Republic of Seoul, Korea, Republic of, 03080 Seoul, Korea, Republic of, 120-752 Collapse <<
  NCT01188252	Neoplasms	Phase 1	Completed	-	United States, Missouri ... more >> St. Louis, Missouri, United States, 63110 United States, New York Buffalo, New York, United States, 14263-0001 United States, Ohio Cleveland, Ohio, United States, 44195 France Caen Cedex, France, 14033 Lyon Cedex, France, 69008 Marseille Cedex 20, France, 13915 Villejuif Cedex, France, 94805 Germany Heidelberg, Baden-Württemberg, Germany, 69120 Herne, Nordrhein-Westfalen, Germany, 44625 Collapse <<

• 更多
• 参考文献

• [1] Yang XH, Tang F, et al. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature). Sci Rep. 2017 Dec;7(1):41.

  [2] Bahleda R, Grilley-Olson JE, et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 May 2.